(Q44760813)

6 December 2017

title

Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma (English)

1 reference

6 December 2017

1 reference

David J Vaughn

1

1 reference

6 December 2017

Archie W Brown

2

1 reference

6 December 2017

W Graydon Harker

3

1 reference

6 December 2017

Sang Huh

4

1 reference

6 December 2017

Lance Miller

5

1 reference

6 December 2017

David Rinaldi

6

1 reference

6 December 2017

Fairooz Kabbinavar

7

1 reference

6 December 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

6 December 2017

1 reference

6 December 2017

volume

100

1 reference

6 December 2017

issue

4

1 reference

6 December 2017

page(s)

746-750

1 reference

Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11956

A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11956

7 January 2021

Nuclear protein matrix as a target for estramustine-induced cell death

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11956

7 January 2021

Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11956

7 January 2021

Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11956

7 January 2021

Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11956

7 January 2021

Phase I trial of weekly paclitaxel in advanced lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11956

7 January 2021

Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11956

7 January 2021

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11956

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11956

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11956

7 January 2021

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11956

7 January 2021

An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11956

7 January 2021

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11956

7 January 2021

Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11956

7 January 2021

Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11956

7 January 2021

Identifiers

DOI

10.1002/CNCR.11956

1 reference

6 December 2017

1 reference